investiment.io
NRx Pharmaceuticals, Inc.
$1.29
0.02 (1.57%)
NRx Pharmaceuticals, Inc.
$1.29
0.02 (1.57%)
NRXP Price Chart
| Basic | |
|---|---|
| Market Cap | $14.62M |
| Price | $1.29 |
| 52 Week Range | 1.1-7.33 |
| Beta | 1.25 |
| Margins | |
| Gross Profit Margin | 62.50% |
| Operating Profit Margin | -255950.00% |
| Net Profit Margin | -254750.00% |
| Valuation (TTM) | |
| P/E Ratio | -0.69 |
| Price to Sales Ratio | 1950.17 |
| Price to Book Ratio | -0.75 |
| PEG Ratio | 0.16 |
Industry
Biotechnology
Sector
Healthcare
Full-Time Employees
2
Website
IPO Date
2017-12-04T00:00:00.000Z
Description
NRX Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. Its products include ZYESAMI, an investigational drug that has completed a Phase IIb/III clinical study for COVID-19 related respiratory failure; and NRX-100 and NRX-101 oral therapeutics for the treatment of bipolar depression in patients with acute suicidal behavior/ideation and sub-acute suicidal ideation and behavior. The company was founded in 2015 and is based in Wilmington, Delaware.
Phone
484 254 6134
Address
1201 Orange Street, Wilmington, DE, 19801, US
CIK
0001719406